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Abstract
Mutations in the human desmin gene cause autosomal-dominant and recessive cardiomyopathies and myopathies with
marked phenotypic variability. Here, we investigated the effects of adeno-associated virus (AAV)-mediated cardiac wild-
type desmin expression in homozygous desmin knockout (DKO) and homozygous R349P desmin knockin (DKI) mice.
These mice serve as disease models for two subforms of autosomal-recessive desminopathies, the former for the one with a
complete lack of desmin protein and the latter for the one with solely mutant desmin protein expression in conjunction with
protein aggregation pathology in striated muscle. Two-month-old mice were injected with either a single dose of 5 × 1012
AAV9-hTNT2-mDes (AAV-Des) vector genomes or NaCl as control. One week after injection, mice were subjected to a
forced swimming exercise protocol for 4 weeks. Cardiac function was monitored over a period of 15 month after injection
and before the mice were sacrificed for biochemical and morphological analysis. AAV-mediated cardiac expression of wild-
type desmin in both the homozygous DKO and DKI backgrounds reached levels seen in wild-type mice. Notably, AAV-Des
treated DKO mice showed a regular subcellular distribution of desmin as well as a normalization of functional and
morphological cardiac parameters. Treated DKI mice, however, showed an aberrant subcellular localization of desmin,
unchanged functional cardiac parameters, and a trend toward an increased cardiac fibrosis. In conclusion, the effect of a
high-dose AAV9-based desmin gene therapy is highly beneficial for the heart in DKO animals, but not in DKI mice.
Introduction
Mutations of the human desmin (DES) gene on chromosome
2q35, which encodes the muscle-specific intermediate fila-
ment protein desmin, cause autosomal-dominant and
autosomal-recessive forms of cardiomyopathies and myo-
pathies [1]. As of today, more than 130 disease-causing gene
alterations comprising missense, small in-frame deletion,
frame shift, and splice site mutations have been reported
(Human Intermediate Filament Database, www.interfil.org)
[1, 2]. Cardiac involvement in desminopathies comprises
hypertrophic, dilated, restrictive, and noncompaction cardio-
myopathies, as well as different forms of often life-threatening
cardiac conduction defects and arrhythmias [2, 3].These authors contributed equally: T. Ruppert, M. B. Heckmann
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While the vast majority of desminopathies show an
autosomal-dominant trait of inheritance and displays mor-
phological signs of protein aggregation pathology in striated
muscle, the very rare autosomal-recessive cases can mean-
while be categorized in three distinct subforms: (1) one with
the complete absence of desmin protein and no obvious pro-
tein aggregation pathology [4–7], (2) one with markedly
reduced protein levels of solely mutant desmin without signs
of protein aggregation [8], and (3) one with markedly reduced
protein levels of solely mutant desmin but the presence of
protein aggregation [9–13]. In contrast to the autosomal-
dominant cases, these recessive forms display a markedly
more severe clinical phenotype and an earlier disease
onset already starting in the first or second decade of life.
Notably, the cardiac involvement determines the unfavorable
prognosis with an early lethality in recessive desminopathies.
No specific treatment for human desminopathies exists to date.
The desmin protein is fibrous in nature and undergoes a
multistep filament assembly process, which finally leads to
the formation of the three-dimensional extrasarcomeric
cytoskeleton in striated muscle cells [14]. This filamentous
desmin network exerts multiple roles in the alignment and
anchorage of myofibrils, the positioning of mitochondria
and myonuclei, mechanosensation, stress endurance, and
cell signaling, and is attached to various intracellular
adhesion sites by members of the spectrin superfamily such
as plectin, nebulin, nebulette, and nesprin [1, 2, 15–17].
Since studies on desmin-related cardiac pathology are
generally hampered by virtual absence of respective human
tissue specimens, animal models for human desminopathies
are valuable tools for molecular analysis and therapeutic
treatment studies. In the present study, we focused on the
therapeutic effect of a high-dose AAV9-mediated expres-
sion of wild-type (WT) desmin on the cardiac pathology in
two autosomal-recessive desminopathy subforms. For the
one with a complete lack of desmin protein we employed
homozygous desmin knockout (DKO) mice [18–20], and
for the one with protein aggregation pathology inflicted by
the sole expression of mutant desmin we used homozygous
R349P desmin knockin (DKI) mice [21]. Since previous
studies showed that the human cardiac troponin T promoter
enables an efficient cardiac gene expression after intrave-
nous injections of AAV9 vectors, [22, 23] we have chosen
this delivery mode also for the current study.
Materials and methods
Animal procedures and study protocol
Two-month-old homozygous DKO mice (B6J.129Sv-
Destm1Cba; http://www.informatics.jax.org/allele/MGI:
2159584, breeding pairs of the latter were received by
courtesy from Denise Paulin, Université Pierre et Marie
Curie, Paris, France) [20] and homozygous R349P DKI
mice (B6J.129Sv-Destm1.1Ccrs; http://www.informatics.jax.
org/allele/MGI:5708562) [21] were treated with AAV-DES
(AAV9-hTNT2-mDes, DKO n= 7, DKI n= 7) [23]; or
NaCl (DKO n= 7, DKI n= 8). Randomization was per-
formed manually shuffling cards. Sample sizes were chosen
based on experiences from previous studies. A dose of 5 ×
1012 vector genomes (VG) was systemically administered
through the tail vein, resulting in a mean body weight (BW)
adjusted dose of ~2.7 × 1014 VG/kg BW. WT littermates
were used as additional controls (WT n= 8). A week after
injection, mice were subjected to a daily 4-week program of
controlled swimming exercise (see Fig. 1a) [24].
Animals were fed ad libitum and housed in a tempera-
ture- and humidity-controlled room in a specified pathogen-
free environment under 12:12 h light/dark cycles. Geno-
typing was performed as previously described [21, 23]. All
procedures involving the use and care of animals were
performed according to the Directive 2010/63/EU of the
European Parliament and the German animal protection
code. Approval was granted by the local ethics review
board (Administrative Council [Regierungspräsidium]
Karlsruhe, Germany, G-143/11).
Left-ventricular function was assessed using transthor-
acic echocardiography before vector application, two weeks
Fig. 1 Study design. a Eight-week-old desmin knockout mice (DKO,
n= 14; AAV-DES, n= 7; NaCl, n= 7) as well as homozygous R349P
desmin knockin mice (DKI, n= 15; AAV-DES, n= 7; NaCl, n= 8) were
injected with a dose of 5 × 1012 of AAV9-hTNT2-mDES (AAV-DES) or
isotonic saline (NaCl). Eight untreated wild-type (WT) mice served as
controls. Swimming experiments were performed in all groups as indi-
cated by the gray rectangle. Mice were assessed by echocardiography
(echo) prior, during and after the swimming exercise at the indicated time
points after starting swimming exercise. Numbers on the right-hand and on
the left-hand sides indicate the animal numbers at the beginning and the
end of the experiment, respectively. Time point of death of animals that
spontaneously died during the experiment are annotated by a cross. b The
AAV-DES vector genome consists of the DES cDNA under control of the
human troponin T2 ( hTNT2) promoter.
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into swimming exercise, upon completion of the swimming
exercise, 6 months and 15 months after vector application.
All measurements were performed investigator blind. Mice
were sacrificed by cervical dislocation and weighed. Hearts
were removed, washed in phosphate-buffered saline (PBS),
weighed and cut in half biventricularily along the SAX of
the left ventricle. One half was embedded in TissueTek
(Sakura, Staufen, Germany) and frozen on dry ice. The
other half was further dissected. Atria and the right ventricle
were removed and snap-frozen. Additional samples from
liver and soleus muscle were taken. All measurements were
performed by a blinded investigator.
Generation of AAV vectors
Murine desmin cDNA was put under the control of the
human troponin T promoter (Fig. 1b) and packaged in
AAV9 capsids by cotransfection of pds_hTNNT2-mDES
[22, 23] together with pDP9rs, a derivate from pDP2rs [25]
with the AAV9 cap gene from p5E18-VD2–9 [26] in
HEK293T cells using polyethylenimine (Sigma Aldrich,
Taufkirchen, Germany). AAV was purified and titrated as
previously described [27].
Swimming exercise protocol
Endurance exercise was carried out as previously described
[24]. Mice were subjected to a step-up swimming protocol
starting with 10 min twice daily increasing the duration by
10 min each day until an exercise duration of 90 min twice
daily was reached. The protocol was ended after 30 days.
Mice were closely observed at all times to avoid hypoxia.
Transthoracic echocardiography
Mice were depilated using Veet Sensitive (Reckitt
Benckiser, Hull, UK). Long axis and short axis (SAX) B-
mode cine loops were obtained. SAX M-mode loops were
taken mid-ventricularly at the papillary muscle level. Ima-
ges were obtained in hand restrained mice using the
Vevo2100 system with a MS400 transducer. Three con-
secutive M-mode measurements of the diastolic posterial
wall thickness (PWTd) were performed. Fractional short-
ening (FS) and left-ventricular enddiastolic diameters were
obtained measuring more than 6 consecutive heartbeats
using the LV-trace function on a SAX M-mode.
Western blot
Heart tissue stored at −80 °C was thawed on ice and
homogenized in lysis buffer (pH 6.8, 5 mM Tris, 10 %SDS,
0.2 M DTT, 1 mM EDTA, 100 mM NaF, 50 mM beta-gly-
cerophosphate, 2 mM Na3VO4, 1 mM PMSF, complete
mini protease inhibitor cocktail (Roche, Mannheim,
Germany)). Three hundred microliters of lysis buffer was
used per 10 mg of cardiac tissue. Tissue was homogenized
using tissue lyser 2 (Qiagen, Hilden, Germany) and dena-
tured by incubation at 95 °C for 5 min, upon which samples
were centrifuged for 10 min at 13,000 rpm. The supernatant
was aliquoted and stored at −20 °C. Lysates were adjusted
to an identical total protein concentration after quantitative
analysis of Coomassie-stained SDS-polyacrylamide gels.
For comparative quantitative blotting, identical total protein
amounts were loaded in all lanes. Gel-electrophoresis was
carried out using a 12% sodium dodecyl sulfate glycine gel
at 80 V for 2.5–3.0 h. Gels were blotted to nitrocellulose
(Whatman Protran BA83; Sigma Aldrich) for 1.5 h with
400 mA. Membranes were blocked with milk powder (5%
in TBS-T) for 1 h on a shaker and washed three times for
10 min with distilled water. Incubation with primary anti-
bodies for desmin (DE-U-10; diluted 1:5000, Merck,
Darmstadt, Germany) and GAPDH (Sigma Aldrich,
1:7500) solved in TBS-T was carried out overnight on a
shaker. Secondary antibodies goat anti-mouse-HRP (Santa
Cruz Biotechnology, Dallas, TX, USA) and goat-antirabbit-
HRP (Santa Cruz Biotechnology) were applied for 1.5 h on
a shaker at a dilution of 1:5000. Membranes were washed
thoroughly in TBS-T after each antibody staining as well as
after antibody stripping (Thermo Scientific, Rockford, IL,
USA) which was performed between desmin and GAPDH
staining. Blots were read out on a ChemiDoc XRX Imaging
System (BioRad) applying Pierce ECL2 western blotting
substrate (Thermo Scientific) following the manufacturer’s
instructions. Expression levels were quantified using Ima-
geJ (NIH, Bethesda, NJ, USA).
Immunofluorescence
Frozen heart tissue embedded in optimal cutting temperature
compound (TissueTek O.C.T. Compound, Sakura Finetek,
Neumatten, Germany) and stored at −80 °C was cut in 9 µm
slices using a Leica CM1950 cryostat and put on microscope
slides. Tissues were fixed in aceton in a −20 °C freezer for
10 min, slowly thawed for ~30min at room temperature and
blocked for 1 h 10% FCS, 1% GS in PBS in a wet chamber.
Slides were incubated with primary antibody RB-alpha-
Desmin (Biozol, Eching, Germany, LS-B2264) diluted 1:75
in PBS and 10% FCS in a wet chamber at 4 °C overnight.
Slides were washed three times for 5 min in PBS. Subse-
quently, the secondary antibody Alexa Fluor 488 goat anti-
rabbit lgG (Thermo Fischer, Dreieich, Germany) was
applied for 1 h in a wet chamber. After washing the slides
three times for 5 min in PBS, cell nuclei were stained with
DAPI 1:1000 in PBS, upon which slides were washed again
and mounted in Mowiol mounting medium. Confocal
microscopy was performed with a Zeiss LSM 780.
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Masson-Trichrome staining
Slides with heart tissue slices of 9 µm thickness were
thawed at room temperature and fixed in 10% formalin for
60 min and refixed in Bouin’s solution overnight to inten-
sify contrast and colors. The next morning, slides were
washed under running tap water (18–26 °C) and nuclei were
stained for 5 min with Weigert’s Hematoxylin and blued for
10 min under lukewarm running tap water to remove excess
of hematoxylin, followed by a short rinse in distilled water.
Cell cytoplasm, muscle, and collagen fibers were stained red
for 5 min in Bieberich scarlet acid fuchsin solution. Slides
were rinsed three times in distilled water for 1 min and
incubated for 10 min with a combination of 1:1 phospho-
tungstic/phosphomolybdic acid solution, to decolorize col-
lagen fibers of Biebrich scarlet acid fuchsin solution and
prepare uptake of aniline blue. The excess solution was
drained on a paper towel, upon which aniline blue solution
was applied for 15 min without rinsing to stain collagen
fibers. Finally, slides were washed three times in distilled
water and dehydrated with graded alcohols in ascending
order (70, 90, 100% EtOH) ending with Xylol for 5 min
prior to mounting with Vitro-Clud mounting medium
(Langenbrinck, Emmendingen, Germany). Images were
acquired on an Olympus BX 51 microscope with an
Olympus XC 30 camera using the cellSens software.
Fibrous tissue was quantified using ImageJ as previously
described [23].
Statistics
Statistics were performed using GraphPad Prism 8
(GraphPad, San Diego, CA, USA). All data are expressed as
mean ± standard error of the mean. Unless stated otherwise,
a one-way-ANOVA was used to test for differences
between groups. The Tukey’s honest significance test was
applied for p value adjustment. A p value below 0.05 was
considered significant.
Results
Aim of our study was to investigate the long-term ther-
apeutic effects of AAV-mediated expression of WT desmin
on the cardiac pathology in two desminopathy mouse
models that were exposed to strenuous exercise. As a model
for the autosomal-recessive desminopathy patients lacking
desmin protein expression we employed DKO mice, which
display a marked cardiac phenotype [19]. As a surrogate for
autosomal-recessive desminopathies with maintained des-
min protein expression and the presence of protein aggre-
gation we used homozygous R349P DKI mice as a model.
The latter display cardiac pathology comprising conduction
defects, arrhythmias, and a late-onset dilated cardiomyo-
pathy [21]. We treated DKO and DKI mice with AAV9-
hTNT2-mDes [23]. In order to study the long-term effect of
AAV-mediated expression of WT desmin in nonsedentary
animals, we subjected these mice and WT siblings to
strenuous exercise employing a swimming protocol at begin
of the study (Fig. 1a). We did not notice a substantial rise in
mortality during the swimming experiments in contrast to a
previous study reporting mortality rates of 50% in desmin
deficient mice subjected to the same swimming protocol
[28].
AAV-mediated cardiac desmin expression in DKO
and DKI mice
Desmin immunoblotting showed that vector-mediated WT
desmin protein expression in AAV-treated DKO hearts
reached a similar level as observed in untreated WT hearts
(Fig. 2a). In hearts of homozygous DKI mice, which display
significantly reduced amounts of solely mutant desmin, [21]
the AAV treatment also led to higher desmin protein
expression levels similar to the ones in WT animals
(Fig. 2b). In order to visualize the subcellular distribution of
desmin after AAV treatment, we performed desmin
immunofluorescence analysis in both models. Notably,
cardiomyocytes of AAV-treated DKO mice showed a des-
min staining pattern that was indistinguishable from that of
WT controls indicating a virtually complete reconstitution
of the typical myofibrillar cross striation and intercalated
disc labeling (Fig. 3a and c, c′ compare with b, b′). In
contrast, analysis of the heart of AAV-treated DKI mice
displayed a more complex pattern. Here, a subset of car-
diomyocytes displayed a cross striation pattern (Fig. 3e′),
while others only showed an intense labeling of intercalated
discs in conjunction with a very weak and incomplete
myofibrillar immunoreactivity (Fig. 3e, e′, e″).
AAV-mediated expression of WT desmin rescues
DKO mice from cardiomyopathy
Mice lacking desmin develop dilated cardiomyopathy
approximately starting 8 months after birth (6 months after
injection, Fig. 4a) [23]. Notably, our high-dose AAV-
mediated expression of WT desmin fully rescued DKO
mice from developing systolic dysfunction. While untreated
DKO mice showed a significant drop in FS between 6 and
15 months from 48 ± 3% to 39 ± 3% (p < 0.05, Welch’s t-
test), AAV-treated DKO mice did not exhibit any sig-
nificant changes in FS (6 months: 52 ± 2%, 15 months: 54 ±
3%) and showed similar values as WT animals (WT
15 months: 50 ± 3%, Fig. 4a). Furthermore, AAV treatment
also significantly reduced cardiac fibrous tissue to levels
close to the WT (Fig. 4b, c).
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AAV-mediated expression of WT desmin does not
reduce cardiac fibrosis in DKI mice
A major drawback of our DKI mice, the model for the
autosomal-recessive desminopathies with maintained des-
min protein expression, is the late-onset and rather mild
form of dilated cardiomyopathy, [21] which is highlighted
by the values of the left-ventricular FS and posterior wall
thickness that were in the same range as in the WT during
the observation time (Fig. 5a). Thus, the effects of the AAV
treatment on functional cardiac parameters cannot be suf-
ficiently evaluated. However, though this was not statisti-
cally significant, we observed a trend toward an increase of
cardiac fibrosis in AAV-treated DKI animals (Fig. 5b, c),
indicating a lack of therapeutic effect.
Discussion
AAV9-mediated expression of WT desmin in DKO
mice: a cure for the cardiac pathology
The very few thus far reported human patients suffering
from a desminopathy due to a complete lack of desmin
protein basically all die from their severe cardiac disease
manifestation [4–7]. Since no specific therapy is currently
available, we here explored the therapeutic effects of a high-
dose AAV9-based expression of WT desmin in the hearts of
DKO mice. In a previous study, we already demonstrated
that a dose of 3 × 1012 VG led to a low-level cardiac re-
expression of desmin (20% as compared with the WT) and
an amelioration of the morphological and functional cardiac
pathology in the treated DKO mice [23]. By further
increasing the dose to 5 × 1012 VG, we were now able to
fully normalize the level of desmin protein in cardiac tissue
of the treated animals. On the morphological level, this was
associated with the complete reconstitution of the three-
dimensional desmin network in virtually all cardiomyo-
cytes. Notably, this successful restoration of the inter-
mediate filament network on the cellular level not only
reversed the degree of cardiac tissue fibrosis, but also led to
a complete normalization of the functional cardiac para-
meters, namely the left-ventricular FS and left-ventricular
posterior wall thickness. Thus, the current study shows that
increasing the AAV dose results in an improved therapeutic
effect in DKO mice.
A previous study reported that strenuous physical exer-
cise led to a mortality rate of up to 50% in DKO mice [28].
Fig. 2 Desmin protein expression following gene therapy in DKO
and DKI mice. a Cardiac desmin protein expression normalized to
wild type in DKO mice next to a western blot stained for desmin and
GAPDH. Expression levels of AAV-treated desmin knockout
(DKO AAV) mice were comparable to the ones observed in wild-type
(WT) mice, while no desmin expression was detectable in untreated
knockout (DKO) mice. Animal numbers, DKO AAV= 5, DKO= 5,
WT= 5. b Cardiac desmin protein expression normalized to wild
type (WT) in DKI mice next to a western blot stained for desmin and
GAPDH. Expression levels of AAV-treated homozygous R349P
desmin knockin (DKI AAV) mice were in the same range as the ones
of the wild-type (WT) mice, while untreated desmin knockin
(DKI) mice exhibited significantly lower amounts of desmin. Animal
numbers, DKI AAV= 5, DKI= 3, WT= 5. *p < 0.05, **p < 0.01,
***p < 0.001.
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This, however, could not be reproduced in the present study,
which employed the same swimming protocol. Out of seven
AAV DKO and seven NaCl DKO mice, only two and one,
respectively, died during the 15-month course of this study.
Here, it is tempting to speculate that the discrepancy might
result from different genetic backgrounds. DKO mice of the
above-mentioned study had a 129 Sv background, while our
DKO mice were in a C57BL/6J background [29]. Moreover,
even different sub-strains of C57BL/6J have been reported
to diverge in their susceptibility to pressure overload
induced heart failure [30]. Our discrepant findings might be
traced back to the fact that C57BL/6J mice seem to be more
resilient to pressure overload and oxidative stress due to a
deletion in the Nnt gene coding for the mitochondrial NAD
(P) transhydrogenase [31].
Translated into the human disease context, our findings
in DKO mice strongly indicate that an AAV9-based gene
therapy approach, even at a single time point, may serve as
a long-term therapeutic measure for this specific group of
desminopathy patients. However, a further clinical
translation will require dose finding studies in a large animal
model and finally patients in order to identify the lowest
effective dose.
Desmin gene therapy in DKI mice: no clear benefit
for the heart
To date no mouse model exists, which truly mirrors the
genetic alterations in human autosomal-recessive desmi-
nopathies with maintained desmin protein expression. As
a surrogate, we used our homozygous R349P DKI mice,
which show desmin protein aggregate pathology as well
as a cardiac phenotype comprising conduction defects,
arrhythmias, and a late-onset dilated cardiomyopathy
[21].
In untreated mice of this model, the desmin protein
level—solely mutant desmin—in cardiac tissue is ~25% of
the desmin amount in WT animals [21]. In analogy to the
treated DKO mice, our gene therapy approach in the
homozygous DKI mice also resulted in seemingly
Fig. 3 Desmin and 4′,6-diamidin-2-phenylindol (DAPI) double-
staining in cardiac muscle tissue. a wild-type (WT), b desmin
knockout (DKO), c AAV-treated DKO (DKO AAV), d homozygous
R349P desmin knockin (DKI), and e AAV-treated DKI (DKI AAV);
boxed areas (in red) are shown at higher magnification in (a′), (b′), (c′),
(d′) as well as (e′) and (e″). The AAV-mediated expression of wild-
type desmin leads to the typical myofibrillar cross striation and
intercalated disc labeling patterns in the cardiomyocytes of desmin
knockout mice as seen in (c) and (c′) as compared to (b) and (b′).
Cardiomyocytes from DKI mice, however, showed a more complex
and inhomogeneous pattern after AAV-mediated expression of wild-
type desmin (e, e′, e″ versus d, d′). While a subset of cardiomyocytes
displayed a cross striation pattern (e′), others only showed an intense
labeling of intercalated discs in conjunction with a very weak and
incomplete myofibrillar immunoreactivity (e″).
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Fig. 5 Effects of AAV-mediated gene therapy on homozygous
R349P desmin knockin mice. a LV fractional shortening and pos-
terior wall thickness of the left ventricle did not differ significantly
between the groups. Animal numbers (0 weeks/2 weeks/
4 weeks/6 months/15 months) DKI AAV (7/6/6/6/5), DKI (8/8/6/5/3),
WT (8/8/8/8/7). b, c Masson-Trichrome staining revealed no statisti-
cally significant effect of AAV-mediated wild-type desmin expression
on the development of cardiac fibrous tissue in homozygous R349P
desmin knockin mice. Animal numbers, DKI AAV= 4, DKI= 3,
WT= 3. *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 4 Effects of AAV-mediated gene therapy on desmin knockout
mice. a AAV-treated knockout mice showed similar left-ventricular
(LV) fractional shortening and left-ventricular posterior wall thickness
as wild-type controls. Untreated DKO animals developed severe left-
ventricular systolic dysfunction and thinning of the posterior wall
between 6 and 15 months. Animal numbers (0 weeks/2 weeks/4
weeks/6 months/15 months) DKO AAV (7/6/5/5/5), DKO (7/7/6/6/6),
WT (8/8/8/8/7). b, c AAV-mediated expression of wild-type desmin led
to a significant reduction in cardiac fibrosis in DKO mice as compared
with untreated controls. Animal numbers, DKO AAV= 5, DKO= 5,
WT= 3. *p < 0.05, **p < 0.01, ***p < 0.001.
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normalized total desmin protein amounts. However, on the
morphological level only a subset of cardiomyocytes dis-
played a normal desmin cross-striated staining pattern
indicating that the individual, cell-specific mixture of WT,
and mutant desmin influences the stability of the desmin
intermediate filament network and the turnover of the dif-
ferent desmin protein species. This notion is in line with our
previous results, in which WT and mutant desmin proteins
displayed different patterns of turnover in skeletal muscle
tissue of heterozygous and homozygous R349P DKI mice
and WT littermates [21]. Notably, the increased desmin
protein levels were also associated with a trend toward an
increase of cardiac fibrosis in AAV-treated DKI animals,
which might reflect a harmful effect on cardiac tissue in this
setting where both WT and mutant desmin proteins are
present.
Out of seven AAV DKI and eight NaCl DKI mice a
number of two and five animals, respectively, died during
the course of this study. However, the applied 4-week
protocol of strenuous exercise did not accelerate the
development of cardiomyopathy in DKI mice during the
long-term follow-up for 15 months after vector injection.
Thus, impaired left-ventricular function can be ruled out as
potential cause. Previous electrophysiological investigation
in R349P DKI mice during swimming exercise documented
an increased number of premature ventricular contractions
and higher grade atrio-ventricular and sinu-atrial blocks
compared with WT controls [21]. However, since there was
no difference in electrophysiological parameters between
homozygous and heterozygous R349P DKI mice in our
previous study, we did not consider potential effects of
desmin-overexpression on electrophysiology and have thus
not performed Holter-EKGs [21]. Although the over-
expression of WT desmin had no beneficial effect on car-
diac fibrosis of DKI mice, further electrophysiological
studies are necessary to investigate whether the trend
toward increased mortality in control-treated DKI mice can
be explained by sudden cardiac death induced by malignant
arrhythmias or conduction defects.
Taken together, in contrast to DKO mice, in which the
expression of WT desmin resulted in a significant reduction
of cardiac fibrosis and protection from heart failure, the
cardiac phenotype of DKI mice, i.e., the extent of cardiac
fibrous tissue, could not be ameliorated by gene transfer of
WT desmin. Thus, future gene therapy approaches for the
cure of cardiomyopathy in desminopathies that are based on
the overexpression of WT desmin appear particularly useful
for patients with a complete lack of desmin protein.
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